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Emerging RegionsIntroduction
The launch of Value in Health Regional Issues in 2012 represented
an important milestone in the development of pharmacoeco-
nomics and outcomes research (PE-OR) in Asia, Central and
Eastern Europe, Western Asia, Africa, and Latin America [1,2]. It
was clear that a new journal was required to accommodate the
rapid growth in studies. In the last 10 years, the sister journal
Value in Health published considerably more articles originating in
these regions, because of both an increase in submissions and
the publication of the best articles from ISPOR’s Asian and Latin
American conferences. We can only expect the volume of
research from these regions to increase, given the combined size
of their population and the rapid growth in interest in PE-OR
studies.Current Status of PE-OR in Emerging Regions
The immediate impression from reading the first two issues of
the new journal is that the content is very similar to that of Value
in Health, in terms of both topics addressed and research methods
used. For example, in the first two issues, the new journal
published 15 economic evaluations, 9 cost-of-illness studies, 4
articles discussing patient-reported outcomes, 2 preference-
based assessments, and 7 health policy analyses or commen-
taries. The methods used were also very familiar, including
different modeling approaches such as state transition models
and discrete event simulation, and different approaches to the
estimation of health state preference measures. As might be
expected, some articles dealt with diseases found mainly in these
regions, such as dengue and hepatitis B [3,4], but the vast
majority concerned diseases that are also very prevalent in
Europe and North America, the regions providing the majority
of articles published in Value in Health. Also, several of the specific
drugs studied were those currently of substantial policy interest
in developed countries, such as sirolimus and tacrolimus [5], or
sunitinib [6].
There were no articles in the first two issues of the new
journal discussing the use of new methodological approaches,
but they did contain several interesting conceptual articles,
discussing the impact of using particular methods, the more
general interaction between policy problems and the methods
used to analyze them, or filling the gap between research and
policy [7].
In short, based on an analysis of the first two issues of the
new journal, there is little difference between the current
practice of PE-OR in the emerging regions and that in the restial support: The author has no other financial relof the world, beyond the fact that, understandably, studies
address the main issues of concern in the countries in which
they are conducted.Challenges
Although this brief analysis of the first two issues of Value in
Health Regional Issues suggests that PE-OR researchers in the
emerging regions have been very active, they still face a number
of challenges. These are discussed under the following headings:
developing local researchers, obtaining data, and clarifying the
decision-making framework.
Developing Local Researchers
A glance at the authorship of the articles in the first two issues of
Value in Health Regional Issues demonstrates that there is already a
critical mass of trained researchers in the emerging regions.
Many of these trained in North America or Europe and in some
cases have conducted research in collaboration with colleagues
from these regions. However, if PE-OR is to expand, there is an
urgent need to establish local training programs because sending
individuals overseas for training is unlikely to keep up with the
demand. There have been many excellent examples of such
programs in the past, such as the International Clinical Epide-
miology Network, which trained numerous researchers in Africa,
Asia, and Latin America. Perhaps funding could be mobilized to
create a similar training program in the field of PE-OR. In some
jurisdictions, including Argentina and Chile, individual research-
ers have taken the initiative to develop training courses and
programs. In addition, some of the ISPOR chapters in the emer-
ging regions have managed to use their funding to sponsor short
training courses. To train researchers of the appropriate caliber,
however, it will be necessary to establish more local postgraduate
programs.
Obtaining Data
Several important categories of data are required to conduct PE-
OR studies, including data on relative treatment effect, epide-
miological data, resource use, and unit costs. Some of this may be
routinely available, or come from studies already being con-
ducted for other purposes. In the case of studies involving
patient-reported outcomes or preference-based assessments,
however, patient-level surveys often need to be conducted,
although some quality-of-life data may come from clinical trials.
Although data on relative treatment effect are widely regarded
as one of the more transferable categories of data [8], it could beationships to disclose.
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different in some jurisdictions in the emerging regions, owing to
differences in supportive care. Interestingly, it is increasingly
common to see patients from clinical centers in the emerging
regions enrolled in major multinational clinical trials, owing to
the lower cost of conducting trials in these settings. In principle,
this should allow more exploration of potential differences in
relative treatment effect across settings, although this opportu-
nity is rarely exploited in the analysis and reporting of trial data.
Epidemiological data have numerous uses in PE-OR studies,
including the assessment of absolute risk in the local patient
population and for extrapolating beyond the follow-up period in
clinical trials. Epidemiological studies normally result from pub-
lic investments in data gathering, and, understandably, these
databases are less prevalent in jurisdictions in the emerging
regions. It will therefore be important to identify sources of
funding for epidemiological studies as the demand for PE-OR
studies grows. One possibility would be for groups of manufac-
turers with products in a given therapeutic area (e.g., diabetes) to
combine forces to make unrestricted grants available to establish
epidemiological databases, such as patient registries.
More investment is also required in data on resource use and
cost. Indeed, in several developed countries, including Australia
and The Netherlands, public sector agencies commissioned the
development of public databases on costs to support the produc-
tion of PE-OR studies, at the time they were mandated by the
reimbursement process for pharmaceuticals in the jurisdictions
concerned. In developed countries, data on resource utilization
are often obtained from administrative databases. It is therefore
worth remembering that several countries in the emerging
regions, including South Korea, Mexico, and Taiwan, have well-
developed social insurance or social security systems, which
offer the potential for gathering data on practice patterns and
resource utilization. However, it will be important to ensure that
such data are made available to those conducting PE-OR studies,
provided they can present a sound case.
Clarifying the Decision-Making Framework
Although PE-OR studies have been conducted for many years in
developed countries, their use and influence was greatly
enhanced once clear processes were established to use study
results in decisions about the pricing, reimbursement, or use of
medicines. For example, the Pharmaceutical Benefits Advisory
Committee in Australia, the Canadian Agency for Drugs and
Technologies in Health in Canada, the Dental and Pharmaceu-
tical Benefits Agency (English translation) in Sweden, and the
National Institute for Health and Clinical Excellence in the United
Kingdom have had a profound impact on the growth of this
research [9].
A similar pattern is developing in the emerging regions, with
Brazil, Mexico, South Korea, Taiwan, and Thailand being among
the first to establish clear processes for the use of PE-OR studies.
In turn, this has stimulated the growth of PE-OR in the jurisdic-
tions concerned. The development of a clear and transparent
decision-making framework, however, is probably the biggest
challenge in many of the countries in the emerging regions. A
survey of researchers and decision makers in the Latin American
region identified a large gap between aspirations for a cleardecision-making framework and that which exists currently
[10]. These developments in decision-making processes are likely
to take time because they cannot be forced from outside. Rather,
decision-making processes in the health care sector need to be
developed in a way consistent with local cultural, political, and
social norms.Conclusions
The field of PE-OR has already grown rapidly in the emerging
regions. The new journal Value in Health Regional Issues will play
an important role in this development because it offers increased
opportunities to researchers to subject their work to the scrutiny
of peer review. If this growth is to be sustained, however,
additional attention will have to be paid to training, data avail-
ability, and the ways in which decision-making processes can
accommodate the use of PE-OR studies.
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